Perfusion of99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target
Open Access
- 9 January 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 109 (3), 436-441
- https://doi.org/10.1002/ijc.11699
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Strategies for vascular targeting in tumorsInternational Journal of Cancer, 2002
- CD105 Antibody for Targeting of Tumor Vascular Endothelial CellsPublished by Springer Science and Business Media LLC ,2002
- Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promotersGene Therapy, 2001
- Genes Expressed in Human Tumor EndotheliumScience, 2000
- An Address System in the Vasculature of Normal Tissues and TumorsAnnual Review of Immunology, 2000
- Clinical applications of angiogenic growth factors and their inhibitorsNature Medicine, 1999
- Fighting Cancer by Attacking its Blood SupplyScientific American, 1996
- EDITORIAL. CD105 AND ANGIOGENESISThe Journal of Pathology, 1996
- Role of angiogenesis in patients with cerebral ischemic stroke.Stroke, 1994
- Vascular attack as a therapeutic strategy for cancerCancer and Metastasis Reviews, 1990